Stocktoria
SAB Biotherapeutics, Inc. SABS
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-12
SAB Biotherapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $1.3M | $2.2M | $23.9M | $60.9M | $55.2M |
| R&D expense | $34.4M | $30.3M | $16.5M | $36.4M | $57.2M | $27.9M |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | -$13.4M | $20.6M |
| Interest expense | — | — | $315,284 | $301,584 | $294,459 | $469,151 |
| Income tax | $0 | $0 | $0 | $25,629 | $0 | $0 |
| Net income | $13.3M | -$34.1M | -$42.2M | -$18.7M | -$17.1M | $20.1M |
| EPS (diluted) | $-0.79 | $-3.68 | $-7.64 | $-4.31 | $-0.63 | $0.74 |
| Operating cash flow | -$44.8M | -$34.3M | -$25.1M | -$23.5M | $2.0M | $10.0M |
| Free cash flow | -$45.7M | -$34.6M | -$25.3M | -$25.6M | -$9.0M | -$2.7M |
| Cash & equivalents | $10.5M | $8.9M | $56.6M | $15.0M | $33.2M | $12.6M |
| Total assets | $172.8M | $44.2M | $83.9M | $50.9M | $81.1M | $56.5M |
| Total liabilities | $21.3M | $18.2M | $26.6M | $19.8M | $42.6M | $17.5M |
| Shareholders' equity | $151.5M | $26.0M | $57.3M | $31.1M | $38.5M | $39.0M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -100.0% | -40.9% | -90.6% | -60.7% | +10.2% | — |
| Net income growth | — | — | — | — | -185.2% | — |
| EPS growth | — | — | — | — | -185.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.